gefitinib has been researched along with quercetin in 11 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (quercetin) | Trials (quercetin) | Recent Studies (post-2010) (quercetin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 12,403 | 239 | 7,510 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Castillo-Pichardo, L; Dharmawardhane, SF | 1 |
| Carbone, ML; Lulli, D; Passarelli, F; Pastore, S | 1 |
| Bal, R; Basak, S; Bisht, G; Kandpal, ND; Karki, N; Pal, M; Sahoo, NG; Tiwari, H; Verma, RK | 1 |
| Shen, Y; TanTai, J | 1 |
11 other study(ies) available for gefitinib and quercetin
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.
Topics: Adenylate Kinase; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Catechin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation; Humans; Mice; Mice, SCID; Polyphenols; Proto-Oncogene Proteins c-akt; Quercetin; Quinazolines; Resveratrol; Signal Transduction; Sirolimus; Stilbenes; TOR Serine-Threonine Kinases; Vitis; Xenograft Model Antitumor Assays | 2012 |
Topical Plant Polyphenols Prevent Type I Interferon Signaling in the Skin and Suppress Contact Hypersensitivity.
Topics: Administration, Topical; Animals; Cells, Cultured; Cetuximab; Chemokine CXCL10; Dermatitis, Allergic Contact; Disease Models, Animal; Gefitinib; Humans; Interferon Regulatory Factor-1; Interferon Type I; Keratinocytes; Mice; Neoplasms; Phosphorylation; Plant Extracts; Polyphenols; Quercetin; Resveratrol; Signal Transduction; STAT1 Transcription Factor | 2018 |
Functionalized graphene oxide as a nanocarrier for dual drug delivery applications: The synergistic effect of quercetin and gefitinib against ovarian cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Female; Gefitinib; Graphite; Humans; Ovarian Neoplasms; Povidone; Quercetin | 2019 |
Co-Delivery Anticancer Drug Nanoparticles for Synergistic Therapy Against Lung Cancer Cells.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Screening Assays, Antitumor; Gefitinib; Humans; Lung Neoplasms; Mice; Molecular Structure; Nanoparticles; Particle Size; Polyesters; Polyethylene Glycols; Quercetin; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |